Essential thrombocythemia
Essential thrombocythemia
... Essential thrombocythemia (ET) is an acquired myeloproliferative disorder (MPD) characterized by a sustained elevation of platelet number with a tendency for thrombosis and ...
17
A case of minor BCR-ABL1 positive acute lymphoblastic leukemia following essential thrombocythemia and originating from a clone distinct from that harboring the JAK2-V617F mutation
... ET: Essential thrombocythemia; JAK2: Janus Kinase 2; HSPCs: Hematopoietic stem and progenitor cells; MPNs: Myeloproliferative neoplasms; PV: Polycythemia vera; PMF: Primary myelofibrosis; AML: Acute myeloid ...
5
The emergence of non secretory multiple myeloma during the non cytotoxic treatment of essential thrombocythemia: a case report
... with essential thrombocythemia is extremely ...of essential thrombocythemia on the development of multiple ...work-up, essential thrombocythemia was ...of essential ...
7
Acute ST-segment elevation myocardial infarction in a young patient with essential thrombocythemia: a case with long-term follow-up report
... Abstract: Essential thrombocythemia (ET) is a neoplastic proliferation of mature myeloid cells – in particular, megakaryocytes – leading to persistently elevated platelet ...
5
Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis
... 6. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D ’ Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe ...
11
Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)
... Essential thrombocythemia (ET) and polycythemia vera (PV) are BCR-ABL–negative myeloproliferative neoplasms (MPN) characterized by an overproduction of mature blood elements, tendencies toward thrombosis ...
13
<p>What cardiologists should know about essential thrombocythemia and acute myocardial infarction: report of two cases and advanced heart failure therapies considerations</p>
... Abstract: We present the cases of two young male patients aged 22 and 31 without prior medical history nor cardiovascular risk factors, who presented to the hospital with large anterior ST-elevation myocardial infarction ...
7
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
... with essential thrombocythemia (ET) and 172 polycythemia vera (PV) patients diagnosed according to the 2016 WHO criteria and with full molecular characterization for driver ...
8
Impact of <em>JAK2</em>(<em>V617F</em>) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study
... Abstract: A JAK2(V617F) mutation is found in approximately 55% of patients with essential thrombocythemia (ET), and represents a key World Health Organization diagnostic criterion. This ...
8
Leukocytosis at Diagnosis in Patients with Essential Thrombocythemia Is a Risk Factor for Transformation into Myelofibrosis
... (MPN), essential thrombocythemia (ET) has the most favourable prognosis in terms of survival and myelofibrosis or leu- kemic transformation: ET is considered usually not to reduce the patient’s life ...
5
Non ST-segment elevation myocardial infarction in patient with essential thrombocythemia
... tirofiban. Essential thrombocythemia was diagnosed based on bone marrow findings, clinical presentation and laboratory ...and essential thrombocythemia is ...
5
Emergency cardiac surgery and heparin resistance in a patient with essential thrombocythemia
... Essential thrombocythemia (ET) is classified as a myelopro- liferative neoplasm. The characteristics are megakaryocyte proliferation in the bone marrow, continuously very high platelet counts (>45 × 10 4 ...
5
Emerging treatments for essential thrombocythemia
... hemorrhagic thrombocythemia to describe a disorder characterized by permanent elevation of a platelet count to more than three times normal, hyperplasia of megakaryocytes, and the tendency for venous thrombosis ...
9
An altered platelet granule glycoprotein in patients with essential thrombocythemia
... The protein profiles of washed platelets from nine patients with essential thrombocythemia were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. In four patients, an additional protein ...
8
Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2 V617F allelic burden
... PV: polycythemia vera; ET: essential thrombocytemia; MPN: myeloproliferative neoplasms; INFα: interferon alpha; PegINFα: pegylated‑interferon alpha; HU: hydroxyurea; PBL: peripheral bl[r] ...
9
Download Download PDF
... ET: Essential thrombocythemia; PMF: Primary myelofibrosis; MPN: Myeloproliferative neoplasm; MPN‑U: Unclassifiable MPNs; JAK2: Janus kinase 2; CALR: Calreticulin; MPL: Myeloproliferative leukemia virus ...
12
Complications and management of coagulation disorders in leukemia patients
... Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Quintás-Cardama A, Kantarjian H, Ravandi F, et[r] ...
12
Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada
... The myeloproliferative neoplasms (MPNs) are clonal myeloid malignancies of the bone marrow classified by their unique genetic etiology and hematological histo- morphologic features. The broadest classification is by ...
5
Familial risks of acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms.
... 7. Rumi E, Passamonti F, Della Porta MG, et al. Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol. 2007;25(35):5630-5635. 8. Landgren O, Goldin LR, ...
9
Myeloproliferative neoplasms (MPNs) – Part 1: An overview of the diagnosis and treatment of the “classical” MPNs
... i.e., essential thrombocythemia [ET], polycythemia vera [PV] and myelofibrosis [MF]) can be significant and can negatively impact quality of life ...an essential role in communicating with these ...
8